Nebula Research & Development LLC Grows Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Nebula Research & Development LLC increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 159.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,469 shares of the medical instruments supplier's stock after buying an additional 5,206 shares during the period. Nebula Research & Development LLC's holdings in LeMaitre Vascular were worth $780,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in LMAT. Smartleaf Asset Management LLC raised its stake in shares of LeMaitre Vascular by 234.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC raised its position in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares during the last quarter. KBC Group NV lifted its holdings in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares in the last quarter. Huntington National Bank grew its position in shares of LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after purchasing an additional 455 shares during the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular during the 4th quarter worth approximately $150,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on LMAT shares. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital upped their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $98.14.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Price Performance

LMAT stock traded down $11.54 on Friday, hitting $78.70. 601,984 shares of the company were exchanged, compared to its average volume of 162,901. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of 43.01, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The business's fifty day moving average is $85.58 and its two-hundred day moving average is $93.34.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's revenue was up 12.0% on a year-over-year basis. During the same period last year, the firm posted $0.44 EPS. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, May 15th. LeMaitre Vascular's dividend payout ratio is presently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.